The grandson of Italian immigrants, Philip John DiSaia was born on Aug. 14, 1937 in Providence, Rhode Island. He earned his Bachelor's in Science at Brown University and his MD at Tufts University.
THE CHECKPOINTS were born in 2007 on an escalator in Chicago. Here's the story…
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has approved Vizimpro (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
FDA has approved Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase and the first approved dual inhibitor of PI3K-delta and PI3K-gamma. Copiktra is approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies.
FDA has granted Qualified Infectious Disease Product and Fast Track designations for the company's prophylaxis development program for its lead antifungal product candidate, rezafungin for injection.
Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Blincyto (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Blincyto was developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
The European Commission has granted marketing authorization to Udenyca (formerly CHS-1701), a pegfilgrastim (Neulasta) biosimilar. Udenyca is one of the first pegfilgrastim biosimilars to gain marketing authorization in Europe.
Findings from the NELSON study demonstrate that the use of computed tomography screening among asymptomatic men at high risk for lung cancer led to a 26 percent (9-41%, 95% CI) reduction in lung cancer deaths at 10 years of study follow-up (at 86% compliance).
Imfinzi (durvalumab) reduced the risk of death by nearly one-third compared to placebo in the phase III PACIFIC trial.
